Spread the love

A recent study from the Mammalian Genetics Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom; and School of Medicine, King’s College London, London, United Kingdom shows that “Loss of Fbw7 Reprograms Adult Pancreatic Ductal Cells into α, δ, and β Cells.” This study was published in the August 7  2014 Cell Stem Cell by Prof Axel Behrens, Rocio Sancho, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based Regenerative therapy for T2D: Argonaute-2 (Ago2) promotes  reprogramming of adult pancreatic ductal cells into α, δ, and β cells via up regulation of Ngn3. This study suggests that Argonaute-2, by increasing the expression of Ngn3 in adult pancreatic ductal cells, it may reprogram adult pancreatic ductal cells into β cells.  Thereby, it may induce the expression of Ngn3, increase insulin secretion and inhibit insulin resistanceTogether, this study suggests that pharmacological formulations encompassing “Argonaute-2 activators” may be used to regenerate  β cells in T2D patients. 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, MiRNA-based Regenerative therapy for T2D: Argonaute-2 (Ago2) promotes  reprogramming of adult pancreatic ductal cells into α, δ, and β cells via up regulation of Ngn3, 13/October/2014, 12.21 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation


Spread the love